HerAnova to present expanded HerResolve validation data at global webinar
HerAnova Lifesciences will present expanded clinical validation results for its HerResolve endometriosis blood test at a global gynecology and obstetrics webinar Nov. 23-24, 2026. The company says the larger cohort showed stronger performance for the non-invasive test, which is designed to help identify endometriosis in symptomatic women, including cases missed by imaging.
Why it matters: - HerResolve is positioned as a non-invasive alternative to help speed up endometriosis evaluation, a condition that often takes years to diagnose. - The new validation data could strengthen confidence in a blood test meant to support triage when ultrasound or MRI does not detect disease.
What happened: - HerAnova Lifesciences said Farideh Bischoff, PhD, chief medical officer and head of diagnostics, will present clinical validation data on HerResolve at the 6th International Webinar on Gynecology and Obstetrics. - The webinar runs Nov. 23-24, 2026. - Bischoff’s talk, titled “Efficacy of a Non-Invasive Multi-Omic Blood Test to Detect Endometriosis among Symptomatic Women,” is scheduled for Nov. 23 from 9:40 to 10:00 a.m. ET. - The presentation will focus on how HerResolve can aid detection in women with suspected endometriosis, including patients whose imaging does not show the disease.
The details: - The validation study used samples from 218 participants to train the machine learning model. - An independent cohort of 277 participants was used for validation. - The conference abstract reports an area under the receiver operating characteristic curve of 0.95, sensitivity of 83% and specificity of 97.5%. - Among women with histologically confirmed endometriosis that transvaginal ultrasound and/or MRI missed, the blood test identified 61.5% of cases. - Bischoff said expanding validation to a cohort 3.5 times larger than the initial study population improved performance rather than reducing it. - Bischoff said the result suggests strength and reproducibility and could give clinicians more confidence at key diagnostic decision points. - HerResolve is a multi-omic blood-based diagnostic assay that combines microRNA, protein and a hormone biomarker through a proprietary machine learning framework. - HerAnova describes HerResolve as the first and only commercially available non-invasive blood test developed to detect endometriosis. - The test is currently available at select IVF and reproductive medicine centers across the United States. - HerAnova says HerResolve is intended for symptomatic women of reproductive age.
Between the lines: - Endometriosis affects about 1 in 10 women of reproductive age, but diagnosis often takes seven to 10 years because the current gold standard is invasive laparoscopic surgery. - HerAnova is framing HerResolve as a triage tool, not a replacement for all existing diagnostics. - The broader clinical message is that non-invasive tests may help direct patients toward further evaluation or empirical treatment sooner.
What's next: - HerAnova will present the data during the webinar session on Nov. 23. - The company directs readers to view the webinar program. - HerAnova plans to continue global research, development and commercialization efforts across diagnostics, therapeutics, medical devices and data analytics.
The bottom line: - HerAnova is using expanded validation data to argue that HerResolve can perform well at larger scale and may help narrow the long diagnostic path for endometriosis.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Transportation World Report
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.